Search research articles
Contact Us
Filters
Showing results (111-120 of 210) with videos related to
Page
of 21
Sort By:
JAMA Oncology
|
May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
Tafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.
JCO Precision Oncology
|
October 5, 2020
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis
Yi Lee, Evan W Clark, Marina S D Milan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M Awad, Patrick M Forde, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
Mark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.
Nature Communications
|
July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Joao V Alessi, Biagio Ricciuti, Xinan Wang, et al.
Journal for Immunotherapy of Cancer
|
December 25, 2024
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings
Brian S Henick, Peter D Koch, Justin F Gainor, et al.
JCO Precision Oncology
|
November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Malini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
JTO Clinical and Research Reports
|
September 30, 2021
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i>-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
Julie R Brahmer, Melissa L Johnson, Manuel Cobo, et al.
Page
of 21
Search research articles
Search
Showing results (111-120 of 210) with videos related to
Sort By:
Page
of 21
JAMA Oncology
|
May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
Tafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.
JCO Precision Oncology
|
October 5, 2020
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis
Yi Lee, Evan W Clark, Marina S D Milan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M Awad, Patrick M Forde, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
Mark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.
Nature Communications
|
July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Joao V Alessi, Biagio Ricciuti, Xinan Wang, et al.
Journal for Immunotherapy of Cancer
|
December 25, 2024
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings
Brian S Henick, Peter D Koch, Justin F Gainor, et al.
JCO Precision Oncology
|
November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Malini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
JTO Clinical and Research Reports
|
September 30, 2021
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i>-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
Julie R Brahmer, Melissa L Johnson, Manuel Cobo, et al.
Page
of 21